Galderma SA:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Galderma SA - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C3317
◆発行会社(調査会社):GlobalData
◆発行日:2018年8月
◆ページ数:36
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スイス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥34,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥69,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥103,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Galderma SA (Galderma), a subsidiary of Nestle SA, is a pharmaceutical company that develops and markets drugs, medical dermatology solutions and therapeutic skin care products for the treatment of hair, nail, and skin diseases. Galderma offers products for the treatment of skin conditions such as seborrheic dermatitis, dry skin, acne, psoriasis, atopic dermatitis, steroid responsive dermatoses, pigmentation disorders, aging skin, onychomycosis, rosacea, skin cancer and others. The company offers products leading brands such as Azzalure, Cetaphil, Clobex, Macrolane, and Oracea among several others. It markets products in India, Greece, Italy, Canada, Chile, Poland, the UK, and the US, among others. The company operates manufacturing facilities in France, Sweden, Canada, Brazil, Germany and Switzerland and research and development (R&D) centers in France, Sweden, the US, Switzerland and Japan. Galderma is headquartered in Lausanne, Switzerland.

Galderma SA – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Galderma SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Galderma SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Galderma SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Galderma SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Galderma SA, Medical Devices Deals, 2012 to YTD 2018 9
Galderma SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Galderma SA, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Galderma to Acquire Assets of Laboratoires Inneov from L’Oreal 11
Galderma Completes Acquisition of Aesthetic Dermatology Assets from Valeant Pharma for USD1.4 Billion 12
Galderma Acquires Pekiron Cream From Kyorin Pharma 13
Partnerships 14
Galderma Enters into Research Agreement with Icahn School of Medicine at Mount Sinai and Northwestern University Feinberg School of Medicine 14
Bioventus Enters into Agreement with Galderma for Durolane in US 15
Galderma Enters into Distribution Agreement with Ipsen for Dysport in Asia-Pacific 16
Galderma Enters into Agreement with ZELTIQ Aesthetics 17
Galderma Enters into Agreement with ImaBiotech 18
Ipsen Extends Distribution Agreement with Galderma for Dysport 19
Ipsen Extends Distribution Agreement With Galderma For Dysport 21
Sinclair IS Pharma Enters Into Co-Promotion Agreement With Galderma For Kelo-cote 22
Licensing Agreements 23
Clementia Pharma Enters into Licensing Agreement with Galderma R&D 23
Galderma Pharma Enters into Licensing Agreement with Chugai Pharma 24
Nuvo Research Enters into Licensing Agreement with Galderma Pharma for Pliaglis 25
Asset Transactions 26
Bioventus Acquires Durolane Assets From Galderma 26
Onset Dermatologics Acquires Worldwide Rights To Clindagel From Galderma Labs 27
STADA Arzneimittel Completes Acquisition Of Generics Business From Spirig Pharma For US$108 Million 28
Acquisition 29
Nestle Completes Acquisition of Remaining 50% Stake in Galderma for USD3.5 Billion 29
Galderma Pharma Acquires Spirig Pharma 30
Galderma SA – Key Competitors 31
Galderma SA – Key Employees 32
Galderma SA – Locations And Subsidiaries 33
Head Office 33
Other Locations & Subsidiaries 33
Appendix 36
Methodology 36
About GlobalData 36
Contact Us 36
Disclaimer 36

List of Tables
Galderma SA, Pharmaceuticals & Healthcare, Key Facts 2
Galderma SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Galderma SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Galderma SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Galderma SA, Deals By Therapy Area, 2012 to YTD 2018 8
Galderma SA, Medical Devices Deals, 2012 to YTD 2018 9
Galderma SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Galderma to Acquire Assets of Laboratoires Inneov from L'Oreal 11
Galderma Completes Acquisition of Aesthetic Dermatology Assets from Valeant Pharma for USD1.4 Billion 12
Galderma Acquires Pekiron Cream From Kyorin Pharma 13
Galderma Enters into Research Agreement with Icahn School of Medicine at Mount Sinai and Northwestern University Feinberg School of Medicine 14
Bioventus Enters into Agreement with Galderma for Durolane in US 15
Galderma Enters into Distribution Agreement with Ipsen for Dysport in Asia-Pacific 16
Galderma Enters into Agreement with ZELTIQ Aesthetics 17
Galderma Enters into Agreement with ImaBiotech 18
Ipsen Extends Distribution Agreement with Galderma for Dysport 19
Ipsen Extends Distribution Agreement With Galderma For Dysport 21
Sinclair IS Pharma Enters Into Co-Promotion Agreement With Galderma For Kelo-cote 22
Clementia Pharma Enters into Licensing Agreement with Galderma R&D 23
Galderma Pharma Enters into Licensing Agreement with Chugai Pharma 24
Nuvo Research Enters into Licensing Agreement with Galderma Pharma for Pliaglis 25
Bioventus Acquires Durolane Assets From Galderma 26
Onset Dermatologics Acquires Worldwide Rights To Clindagel From Galderma Labs 27
STADA Arzneimittel Completes Acquisition Of Generics Business From Spirig Pharma For US$108 Million 28
Nestle Completes Acquisition of Remaining 50% Stake in Galderma for USD3.5 Billion 29
Galderma Pharma Acquires Spirig Pharma 30
Galderma SA, Key Competitors 31
Galderma SA, Key Employees 32
Galderma SA, Other Locations 33
Galderma SA, Subsidiaries 33

List of Figures
Galderma SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Galderma SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Galderma SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Galderma SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Galderma SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Galderma SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Galderma SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Galderma SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Galderma SA, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Galderma SA:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Baron Oil Plc (BOIL):石油・ガス:M&Aディール及び事業提携情報
    Summary Baron Oil Plc (Baron Oil), formerly Gold Oil PLC is an oil and gas exploration and production company. The company identifies and develops crude oil and natural gas interests in Latin America including Peru and Colombia. It holds working interests of Nancy Burdine Maxine oil field, oil and g …
  • Dignitana AB (DIGN):企業の財務・戦略的SWOT分析
    Dignitana AB (DIGN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • BioView Ltd (BIOV):企業の財務・戦略的SWOT分析
    BioView Ltd (BIOV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Xintela AB (XINT):企業の財務・戦略的SWOT分析
    Summary Xintela AB (Xintela) is a biomedical company that develops treatment for cartilage damage and brain tumors. The company’s technology includes Xinmark, a patented marker technology developed to identify and select certain types of tumor cells, which can develop into cartilage cells. It also p …
  • ISS AS:企業のM&A・事業提携・投資動向
    ISS AS - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's ISS AS Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital rais …
  • Faurecia S.A.:企業の戦略・SWOT・財務分析
    Faurecia S.A. - Strategy, SWOT and Corporate Finance Report Summary Faurecia S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • A.G.Barr p.l.c.:企業の戦略・SWOT・財務情報
    A.G.Barr p.l.c. - Strategy, SWOT and Corporate Finance Report Summary A.G.Barr p.l.c. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • SPI Pharma Inc:企業の戦略的SWOT分析
    SPI Pharma Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • RHÖN-KLINIKUM AG:企業の戦略・SWOT・財務分析
    RHÖN-KLINIKUM AG - Strategy, SWOT and Corporate Finance Report Summary RHÖN-KLINIKUM AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Groupe Bruxelles Lambert SA (GBLB):企業の財務・戦略的SWOT分析
    Groupe Bruxelles Lambert SA (GBLB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • J.Crew Group, Inc.:企業の戦略・SWOT・財務情報
    J.Crew Group, Inc. - Strategy, SWOT and Corporate Finance Report Summary J.Crew Group, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • BioMotiv LLC:製薬・医療:M&Aディール及び事業提携情報
    Summary BioMotiv LLC (BioMotiv) is a therapeutics licensing and development service provider. The company offers therapeutics across wide disease areas including proteins, small molecules, antibodies, and nucleotides. It portfolio includes psoriasis, inflammatory bowel diseases, cancer, retinitis pi …
  • Wausau Paper Corporation:企業の戦略・SWOT・財務情報
    Wausau Paper Corporation - Strategy, SWOT and Corporate Finance Report Summary Wausau Paper Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • DASAN ZHONE SOLUTIONS, INC.:企業の戦略・SWOT・財務情報
    DASAN ZHONE SOLUTIONS, INC. - Strategy, SWOT and Corporate Finance Report Summary DASAN ZHONE SOLUTIONS, INC. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Steel Connect, Inc. (STCN):企業の財務・戦略的SWOT分析
    Steel Connect, Inc. (STCN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Institute for Molecular Medicine Finland:製薬・医療:M&Aディール及び事業提携情報
    Summary Institute for Molecular Medicine Finland (FIMM) is a research institute that conducts research activities in the fields of human genomics and personalized medicine. The institute develops diagnostics, treatment and prevention of common health problems using Finnish clinical and epidemiologic …
  • Composites Horizons, Inc.:企業の戦略・SWOT・財務分析
    Composites Horizons, Inc. - Strategy, SWOT and Corporate Finance Report Summary Composites Horizons, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Sigma Pharmaceuticals Limited:戦略・SWOT・企業財務分析
    Sigma Pharmaceuticals Limited - Strategy, SWOT and Corporate Finance Report Summary Sigma Pharmaceuticals Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Covanta Holding Corp (CVA):企業の財務・戦略的SWOT分析
    Covanta Holding Corp (CVA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Midmark Corp-医療機器分野:企業M&A・提携分析
    Summary Midmark Corp (Midmark) is a medical device company that manufactures and markets medical, dental and veterinary healthcare equipments. The company offers medical products such as power procedures tables and chairs, power examination tables, manual examination tables, lighting products, and i …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆